# NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease

> **NCT06622668** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Intellia Therapeutics**

## Conditions studied

- Lung Disease
- Pulmonary Disease
- AATD
- Alpha-1 Antitrypsin Deficiency
- Alpha-1 Antitrypsin Deficiency-associated Lung Disease

## Interventions

- **BIOLOGICAL:** Biological NTLA-3001

## Key facts

- **NCT ID:** NCT06622668
- **Lead sponsor:** Intellia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-11-20
- **Primary completion:** 2025-01-09
- **Final completion:** 2025-01-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Clinical trial ITL-3001-CL-101 for the investigational product NTLA-3001 was withdrawn due to prioritization of other Sponsor programs.
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06622668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06622668, "NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06622668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*